Current situation and analysis of factors affecting non-mechanical tube blockage during hyperthermic intraperitoneal chemotherapy_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DENG Yinyong , HE Yuhua , JIANG Lili ,  YANG Jie

Colorectal Cancer Center, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

YANG Jie, Email: 645946195@qq.com

Keywords：

hyperthermic intraperitoneal chemotherapy; non-mechanical tube blockage; influencing factor

DOI：

10.7507/1007-9424.202211018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the current situation and factors affecting tube blockage (non-mechanical) during hyperthermic intraperitoneal chemotherapy (HIPEC). Methods According to the inclusion and exclusion criteria, the patients with malignant tumors who underwent HIPEC in the Department of Gastroenterology of West China Hospital of Sichuan University from May 2019 to May 2021 were retrospectively gathered. The information about the patient and the occurrence of occlusion during HIPEC were obtained by consulting electronic medical records and perfusion records. The logistic regression analysis was performed to analyze the factors influencing non-mechanical tube blockage during HIPEC. Results A total of 240 patients with malignant tumors were gathered. During HIPEC, the non-mechanical tube blockage occurred in 88 patients with malignant tumors, with the incidence of 36.7%. The multivariate analysis results by logistic regression showed that the probabilities of non-mechanical tube blockage during HIPEC were higher in the patients with age≥65 years (OR=2.142, P=0.016), diabetes mellitus (OR=2.326, P=0.007), perfusion speed of 300–450 mL/min (OR=2.778, P=0.001), ascites (OR=2.192, P=0.020), and PCI ≥20 points (OR=4.380, P<0.001). Conclusions Patients with malignant tumors treated with HIPEC are prone to non-mechanical tube blockage. The patients with middle-aged and elderly, diabetes, low perfusion speed, ascites, and high PCI score need to be of great concern, so as to prevent and deal with tube blockage in time.

Citation： DENG Yinyong, HE Yuhua, JIANG Lili, YANG Jie. Current situation and analysis of factors affecting non-mechanical tube blockage during hyperthermic intraperitoneal chemotherapy. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(4): 456-459. doi: 10.7507/1007-9424.202211018 Copy

1.	Leebmann H, Piso P. Hyperthermic intraperitoneal chemotherapy. Chirurg, 2019, 90(7): 593-604.
2.	Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2): 256-260.
3.	Manzanedo I, Pereira F, Rihuete CC, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol, 2019, 26(8): 2615-2621.
4.	Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer, 2020, 127: 76-95.
5.	Marrelli D, Petrioli R, Cassetti D, et al. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage Ⅲ primary ovarian cancer. Surg Oncol, 2021, 37: 101523. doi: 10.1016/j.suronc.2021.101523.
6.	Bondar OV, Chetverikov SH, Maksymovskyi VY, et al. The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis. Contemp Oncol (Pozn), 2021, 25(4): 270-278.
7.	Überrück L, Nadiradze G, Yurttas C, et al. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol, 2021, 28(7): 3823-3830.
8.	Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. Curr Oncol, 2020, 27(3): 146-154.
9.	中国抗癌协会腹膜肿瘤专业委员会, 广东省抗癌协会肿瘤热疗专业委员会. 中国腹腔热灌注化疗技术临床应用专家共识(2019版). 中华医学杂志, 2020, 100(2): 89-96.
10.	Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
11.	Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 263-288.
12.	Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 359-374.
13.	Onaedo I,Marjolein D, Nadine K, et al. Demographic characteristics and outcomes of surveyed community health workers who utilized mobile for mothers [age group]. PLOS One, 2018. doi.org/10.1371/journal.pone.0194927.t007.
14.	中国肥胖问题工作组数据汇总分析协作组. 我国成人体重指数和腰围对相关疾病危险因素异常的预测价值: 适宜体重指数和腰围切点的研究. 中华流行病学杂志, 2002, 23(1): 10-15.
15.	詹宏杰, 梁寒. 腹腔热灌注化疗在腹膜癌中的应用现状. 肿瘤防治研究, 2021, 48(4): 327-332.
16.	Gurusamy K, Vale CL, Pizzo E, et al. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness. BMJ Open, 2020, 10(5): e039314. doi: 10.1136/bmjopen-2020-039314.
17.	中国抗癌协会妇科肿瘤专业委员会, 中国妇科腹腔热灌注化疗技术临床应用专家协作组. 妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019). 中国实用妇科与产科杂志, 2019, 35(2): 194-201.
18.	Ljunggren M, Nordenvall C, Palmer G. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Eur J Surg Oncol, 2021, 47(11): 2865-2872.
19.	朱晓慧, 甄莉, 吴慧琴, 等. 腹腔热灌注化疗过程中管路不通的原因分析及护理. 全科护理, 2018, 16(11): 1367-1369.
20.	梁英, 廖雪梅. 对手术后的卵巢癌患者进行腹腔热灌注化疗时发生循环灌注不畅的原因分析. 当代医药论丛, 2019, 17(20): 215-216.
21.	苗凯玲, 李春燕, 侯惠如. 恶性胸腔积液引流管堵塞或引流不畅的影响因素. 武警医学, 2018, 29(9): 857-860.
22.	桑秀波, 李晓玉, 龚萍, 等. 肿瘤细胞减灭术加腹腔热灌注化疗治疗卵巢癌的术后不良事件分析. 临床肿瘤学杂志, 2022, 27(2): 148-152.
23.	丁平安, 杨沛刚, 田园, 等. 腹腔热灌注化疗在胃癌治疗规范化实施中的经验分享. 肿瘤综合治疗电子杂志, 2021, 7(3): 51-54.
24.	Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year National French Practice. Ann Surg, 2020, 272(5): 847-854.
25.	Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS^®) Society Recommendations—Part Ⅰ: preoperative and intraoperative management. Eur J Surg Oncol, 2020, 46(12): 2292-2310.

1. Leebmann H, Piso P. Hyperthermic intraperitoneal chemotherapy. Chirurg, 2019, 90(7): 593-604.
2. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2): 256-260.
3. Manzanedo I, Pereira F, Rihuete CC, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol, 2019, 26(8): 2615-2621.
4. Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer, 2020, 127: 76-95.
5. Marrelli D, Petrioli R, Cassetti D, et al. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage Ⅲ primary ovarian cancer. Surg Oncol, 2021, 37: 101523. doi: 10.1016/j.suronc.2021.101523.
6. Bondar OV, Chetverikov SH, Maksymovskyi VY, et al. The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis. Contemp Oncol (Pozn), 2021, 25(4): 270-278.
7. Überrück L, Nadiradze G, Yurttas C, et al. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol, 2021, 28(7): 3823-3830.
8. Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. Curr Oncol, 2020, 27(3): 146-154.
9. 中国抗癌协会腹膜肿瘤专业委员会, 广东省抗癌协会肿瘤热疗专业委员会. 中国腹腔热灌注化疗技术临床应用专家共识(2019版). 中华医学杂志, 2020, 100(2): 89-96.
10. Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
11. Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 263-288.
12. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 359-374.
13. Onaedo I,Marjolein D, Nadine K, et al. Demographic characteristics and outcomes of surveyed community health workers who utilized mobile for mothers [age group]. PLOS One, 2018. doi.org/10.1371/journal.pone.0194927.t007.
14. 中国肥胖问题工作组数据汇总分析协作组. 我国成人体重指数和腰围对相关疾病危险因素异常的预测价值: 适宜体重指数和腰围切点的研究. 中华流行病学杂志, 2002, 23(1): 10-15.
15. 詹宏杰, 梁寒. 腹腔热灌注化疗在腹膜癌中的应用现状. 肿瘤防治研究, 2021, 48(4): 327-332.
16. Gurusamy K, Vale CL, Pizzo E, et al. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness. BMJ Open, 2020, 10(5): e039314. doi: 10.1136/bmjopen-2020-039314.
17. 中国抗癌协会妇科肿瘤专业委员会, 中国妇科腹腔热灌注化疗技术临床应用专家协作组. 妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019). 中国实用妇科与产科杂志, 2019, 35(2): 194-201.
18. Ljunggren M, Nordenvall C, Palmer G. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Eur J Surg Oncol, 2021, 47(11): 2865-2872.
19. 朱晓慧, 甄莉, 吴慧琴, 等. 腹腔热灌注化疗过程中管路不通的原因分析及护理. 全科护理, 2018, 16(11): 1367-1369.
20. 梁英, 廖雪梅. 对手术后的卵巢癌患者进行腹腔热灌注化疗时发生循环灌注不畅的原因分析. 当代医药论丛, 2019, 17(20): 215-216.
21. 苗凯玲, 李春燕, 侯惠如. 恶性胸腔积液引流管堵塞或引流不畅的影响因素. 武警医学, 2018, 29(9): 857-860.
22. 桑秀波, 李晓玉, 龚萍, 等. 肿瘤细胞减灭术加腹腔热灌注化疗治疗卵巢癌的术后不良事件分析. 临床肿瘤学杂志, 2022, 27(2): 148-152.
23. 丁平安, 杨沛刚, 田园, 等. 腹腔热灌注化疗在胃癌治疗规范化实施中的经验分享. 肿瘤综合治疗电子杂志, 2021, 7(3): 51-54.
24. Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year National French Practice. Ann Surg, 2020, 272(5): 847-854.
25. Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS^®) Society Recommendations—Part Ⅰ: preoperative and intraoperative management. Eur J Surg Oncol, 2020, 46(12): 2292-2310.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Current situation and analysis of factors affecting non-mechanical tube blockage during hyperthermic intraperitoneal chemotherapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content